UCB Korea said its dual inhibitor targeting interleukin-17A and 17F, Bimzelx (ingredient: bimekizumab), has been approved by the Ministry of Food and Drug Safety (MFDS) for the treatment of moderate-to-severe plaque psoriasis in adults who require phototherapy or systemic therapy. According to UCB, Bimzelx is the first and only treatment for plaque psoriasis that simultaneously inhibits IL-17A and IL-17F, cytokines that play a central role in the inflammatory process associated with psoriasis. ....
Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate-to-severe plaque psoriasis in adults, receives health insurance benefits in Korea for treating adult patients with chr...
Bimzelx is an injectable medicine. Here’s how it treats moderate to severe plaque psoriasis.
to severe, with large, thick plaques to red inflamed skin affecting the entire body surface.... Picture of plaque psoriasis on the legs. Source: iStock.com. The types of psoriasis include...
The PBS subsidises biological medicines for patients with severe chronic plaque psoriasis.
Learn about the top treatments used to clear up moderate to severe psoriasis.
Read more about ENBREL® (etanercept) for patients, 4 years and older, with moderate to severe plaque psoriasis. See Full Prescribing & Safety Info.
Listen to dermatologist Jerry Bagel, M.D., share guidance for older adults on how to manage their plaque psoriasis symptoms, provide an overview of ILUMYA® (tildrakizumab-asmn), and discuss how to...
Read about how Otezla® can help your kids and teens with moderate to severe plaque psoriasis. See full prescribing & safety info.
with severe plaque psoriasis. The data showed Cosentyx reduced psoriasis severity at Week 12 compared with placebo as demonstrated by the following efficacy results by baseline weight...